for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Opko Health Inc.

OPK.O

Latest Trade

2.10USD

Change

-0.00(-0.00%)

Volume

2,521,853

Today's Range

2.04

 - 

2.18

52 Week Range

1.73

 - 

3.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.10
Open
2.15
Volume
2,521,853
3M AVG Volume
72.37
Today's High
2.18
Today's Low
2.04
52 Week High
3.94
52 Week Low
1.73
Shares Out (MIL)
615.60
Market Cap (MIL)
1,289.68
Forward P/E
-5.03
Dividend (Yield %)
--

Next Event

Q3 2019 OPKO Health Inc Earnings Release

Latest Developments

More

Opko Health Says Qtrly Loss Per Share $0.10

OPKO Health Inc Reports 7.0% Share Stake In Xenetic Biosciences

Opko Health Submits De Novo Request to FDA For The 4Kscore® Test

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Opko Health Inc.

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Industry

Biotechnology & Drugs

Contact Info

4400 Biscayne Blvd

+1.305.5754138

http://www.opko.com

Executive Leadership

Phillip Frost

Chairman of the Board, Chief Executive Officer

Geoff Monk

President

Jane H. Hsiao

Vice Chairman of the Board, Chief Technical Officer

Adam E. Logal

Chief Financial Officer, Senior Vice President

Jon Roger Cohen

Executive Chairman of BioReference Laboratories

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.2K

2017

1.1K

2018

1.0K

2019(E)

0.9K
EPS (USD)

2016

-0.050

2017

-0.490

2018

-0.270

2019(E)

-0.417
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.40
Price To Book (MRQ)
0.75
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
17.24
LT Debt To Equity (MRQ)
16.41
Return on Investment (TTM)
-10.80
Return on Equity (TTM)
-9.52

Latest News

Latest News

Opko Health says over 400,000 customers likely affected by data breach

Opko Health Inc said on Thursday it was notified by its former billing collections vendor about unauthorized access to information on about 422,600 customers, making it the third healthcare company to be affected by the incident.

UPDATE 1-IFR Americas ECM Pipeline

PRICED Invesco Mortgage Capital (US, mortgage REIT) – $220m Block. 14m shares (100% prim) at $15.73 versus $15.73 fixed-price marketing and $16.30 last sale. MS, CITI, CS. Marcus Corporation (US, movie theaters) – $60.4m Block. 1.5m shares (100% sec) at $40.25 versus $40.25...

BRIEF-Opko Plans To Address Draft Local Coverage Determination Published By Novitas Solutions For 4Kscore Test

* OPKO PLANS TO ADDRESS DRAFT LOCAL COVERAGE DETERMINATION PUBLISHED BY NOVITAS SOLUTIONS FOR 4KSCORE TEST Source text for Eikon: Further company coverage:

BRIEF-Opko Health Reports Q1 Loss Per Share Of $0.08

* Q1 REVENUE $254.9 MILLION VERSUS I/B/E/S VIEW $236.9 MILLION

BRIEF-OPKO Health Inc Says Intends To Remain On Tel Aviv Stock Exchange

* OPKO HEALTH INC - INTENDS TO REMAIN ON TEL AVIV STOCK EXCHANGE AND WITHDRAW ITS REQUEST TO VOLUNTARILY DELIST ITS COMMON STOCK FROM TASE

BRIEF-Opko Health Says Board Resolved To Voluntary Delist Common Stock From Tel Aviv Stock Exchange SEC Filing

* OPKO HEALTH SAYS BOARD RESOLVED TO VOLUNTARY DELIST COMMON STOCK FROM TEL AVIV STOCK EXCHANGE - SEC FILING Source text: (https://bit.ly/2v5nNYg) Further company coverage:

BRIEF-OPKO Health Qtrly Diluted Loss Per Share $0.38

* OPKO HEALTH REPORTS 2017 FOURTH QUARTER BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS

BRIEF-Opko Health qtrly loss per share $0.08

* Opko Health reports 2017 third quarter highlights and financial results

BRIEF-OPKO Health submits premarket approval application with FDA for PSA test

* OPKO Health submits premarket approval application with FDA for a point-of-care PSA test with the Claros 1 platform

BRIEF-Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy

* Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy

BRIEF-Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee in Japan

* Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee® in Japan

BRIEF-Opko Health reports 5.11 pct Passive Stake in Rxi Pharmaceuticals

* Opko Health reports 5.11 pct passive stake in RXi Pharmaceuticals Corp as of Dec 21, 2016 - SEC filing Source text: (http://bit.ly/2jJqgB2) Further company coverage:

Growth hormone deficiency drug from OPKO and Pfizer fails study

OPKO Health Inc said its experimental drug for growth hormone deficiency (GHD) in adults failed to provide a statistically significant benefit over a placebo in a late-stage study, sending its shares down about 17 percent on Friday.

BRIEF-OPKO Health to begin shipments of Rayaldee capsules to U.S. distributors on Nov. 29

* Will commence shipments of Rayaldee (Calcifediol) extended-release capsules to distributors in U.S. on Tuesday, November 29, 2016 Source text for Eikon: Further company coverage:

BRIEF-OPKO presents data on RAYALDEE at ASN kidney week 2016

* OPKO Health -Data showed that RAYALDEE has similar effectiveness and safety in controlling SHPT in both AA and NAA patients with stage 3 or 4 CKD Source text for Eikon: Further company coverage:

BRIEF-Opko Health reports Q3 financial and operating results

* Q3 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S

BRIEF-Opko Health anounced entry into animal health market

* Anounced entry into animal health market Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up